C. Gabay

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
C Gabay, C. Gabay, Cem Gabay
Publication record
398 papers · 33,996 citations · H-index 73

PAPERS

IL-18 Binding Protein–Producing Cells Attenuate Anemia in Murine Macrophage Activation Syndrome
20238 citationsauthor #5
The role of interleukin-18 and interleukin-18 binding protein in K/BxN serum transfer-induced arthritis
20233 citationsauthor #6
Detection of Free Bioactive IL-18 and IL-18BP in Inflammatory Disorders.
20233 citationsauthor #5
Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases
20230 citationsauthor #5
Targeted removal of macrophage-secreted interleukin-1 receptor antagonist protects against lethal Candida albicans sepsis.
202331 citationsauthor #14
The cytosolic DNA sensor AIM2 promotes Helicobacter‐induced gastric pathology via the inflammasome
202313 citationsauthor #9
Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach
202214 citationsauthor #8
Cross-talk between IL-6 trans-signaling and AIM2 inflammasome/IL-1β axes bridge innate immunity and epithelial apoptosis to promote emphysema
202220 citationsauthor #12
Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls.
20222 citationsauthor #4
Structural basis of human IL-18 sequestration by the decoy receptor IL-18 binding protein (IL-18BP) in inflammation and tumor immunity
20222 citationsauthor #4
Structural basis of human IL-18 sequestration by the decoy receptor IL-18 binding protein in inflammation and tumor immunity
202219 citationsauthor #4
Special Issue "IL-1 family cytokines in host defense, inflammation and cancer".
20220 citationsauthor #2
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
202260 citationsauthor #27
Reporting and Representativeness of Race, Ethnicity, and Socioeconomic Status in Systemic Sclerosis Randomized Trials: An Observational Study
20224 citationsauthor #3
The Role of Interleukin 18/Interleukin 18-Binding Protein in Adult-Onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis
202220 citationsauthor #3
Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling
202236 citationsauthor #17
Discrimination of COVID‐19 From Inflammation‐Induced Cytokine Storm Syndromes Using Disease‐Related Blood Biomarkers
202143 citationsauthor #12
Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints.
202166 citationsauthor #2
Balance between Interleukin-18 and Interleukin-18 binding protein in auto-inflammatory diseases.
202139 citationsauthor #4
Work and rehabilitation PARE0016 IMPACT OF AXIAL SPONDYLOARTHRITIS ON PATIENTS’ PROFESSIONAL LIFE: RESULTS FROM THE ONLINE SURVEY EMAS OF 638 FRENCH PATIENTS
20210 citationsauthor #6
Excess Serum Interleukin‐18 Distinguishes Patients With Pathogenic Mutations in PSTPIP1
202132 citationsauthor #8
Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritis.
202116 citationsauthor #12
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
202081 citationsauthor #7
Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail
202074 citationsauthor #8
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
202025 citationsauthor #17
IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis
202048 citationsauthor #7
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis
2020100 citationsauthor #8
Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational study.
20202 citationsauthor #3
Intracellular IL-1 Receptor Antagonist Isoform 1 Released from Keratinocytes upon Cell Death Acts as an Inhibitor for the Alarmin IL-1α
202019 citationsauthor #7
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries.
202065 citationsauthor #24
Randomized clinical trials in ANCA-associated vasculitis: a systematic analysis of the WHO - International Clinical Trials Registry Platform
20202 citationsauthor #5
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities
202023 citationsauthor #8
Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies
20201 citationsauthor #5
The role of the IL-1 system in pregnancy and the use of IL-1 system markers to identify women at risk for pregnancy complications†
202044 citationsauthor #6
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools.
20202 citationsauthor #9
Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the disease.
202013 citationsauthor #7
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
202039 citationsauthor #1
Production of IL-18 Binding Protein by Radiosensitive and Radioresistant Cells in CpG-Induced Macrophage Activation Syndrome
202017 citationsauthor #5
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution.
201914 citationsauthor #11
THU0075 EARLY VERSUS DELAYED START OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A PHASE 3 TRIAL OF PATIENTS NAÏVE TO METHOTREXATE TREATMENT
20190 citationsauthor #4
Synovial tissues concentrate secreted APRIL GABAY , Cem
20190 citationsauthor #1
SAT0588 COMPARATIVE EFFECTIVENESS RESEARCH IN OBSERVATIONAL SETTINGS: EVALUATING TWO NEW METHODS TO ANALYSE RESPONSE RATES
20191 citationsauthor #3
AB0262 SERUM CALPROTECTIN AS A MARKER OF DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS
20190 citationsauthor #8
[Inflammatory arthritides pathotypes].
20190 citationsauthor #4
Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritis
201915 citationsauthor #8
Response to: ‘When binary and continuous responses disagree’ by Dr Ouyang
20191 citationsauthor #3
AB1368-HPR ENHANCED ROLE OF NURSES AND OTHER HEALTHCARE PROFESSIONALS (HCPS) IN THE CARE OF RHEUMATOID ARTHRITIS AND ASSOCIATED COMORBIDITIES
20191 citationsauthor #2
Biological agents in the management of adult-onset Still's disease.
20194 citationsauthor #2
The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritis
201916 citationsauthor #8
P097 Intracellular interleukin-1 receptor antagonist released upon cell death acts as an alarmin inhibitor in aldara cream-induced psoriasis-like skin inflammation
20190 citationsauthor #5
Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab
201911 citationsauthor #2
IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome.
201965 citationsauthor #5
Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study.
201925 citationsauthor #9
IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.
201997 citationsauthor #7
PARE0018 ENABLING PATIENT-CENTRED CARE IN RHEUMATOID ARTHRITIS AND ASSOCIATED COMORBIDITIES
20191 citationsauthor #8
Inadequate reporting of concomitant medications in rheumatology randomized controlled trials of pharmacologic interventions.
20191 citationsauthor #3
P093/O16 IL-36 signaling in keratinocytes is mandatory in imiquimod-induced psoriasis in mice
20192 citationsauthor #5
OP0030 RANDOMIZED CONTROLLED 24-WEEK TRIAL EVALUATING THE SAFETY AND EFFICACY OF BLINDED TAPERING VERSUS CONTINUATION OF LONG-TERM PREDNISONE (5 MG/D) IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED LOW DISEASE ACTIVITY OR REMISSION ON TOCILIZUMAB
20198 citationsauthor #7
Long‐term therapy with anakinra in hidradenitis suppurativa in three patients
201923 citationsauthor #3
SAT0687 EVOLVING THE MANAGEMENT OF RHEUMATOID ARTHRITIS THROUGH DEVELOPMENT OF PRACTICAL AND EDUCATIONAL TOOLS
20192 citationsauthor #10
Prevotella copri in individuals at risk for rheumatoid arthritis
2019364 citationsauthor #7
SAT0677 Prevotella copri in individuals at risk for rheumatoid arthritis
20182 citationsauthor #7
β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin Secretion.
201861 citationsauthor #12
Inflammasome Adaptor ASC Suppresses Apoptosis of Gastric Cancer Cells by an IL18-Mediated Inflammation-Independent Mechanism.
201862 citationsauthor #17
[Management of septic arthritis].
20184 citationsauthor #3
Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort
201817 citationsauthor #4
Osteoarthritis Therapy: Nanocrystal–Polymer Particles: Extended Delivery Carriers for Osteoarthritis Treatment (Small 8/2018)
20180 citationsauthor #4
Regulation and function of interleukin‐36 cytokines
2018178 citationsauthor #3
Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis
201863 citationsauthor #5
THU0202 Comparative effectiveness of tocilizumab as monotherapy versus tnf inhibitors in combination with conventional synthetic disease modifying antirheumatic drugs in bio-naÏve patients with rheumatoid arthritis
20180 citationsauthor #16
Variable domain N‐linked glycosylation and negative surface charge are key features of monoclonal ACPA: Implications for B‐cell selection
201844 citationsauthor #11
Nanocrystal-Polymer Particles: Extended Delivery Carriers for Osteoarthritis Treatment.
201867 citationsauthor #4
Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice.
2018117 citationsauthor #7
Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
201825 citationsauthor #14
Prolonged treatment with Tadekinig alfa in adult-onset Still’s disease
201854 citationsauthor #6
SAT0692 Breastfeeding is not associated with anti-citrullinated antibodies development in individuals at risk for rheumatoid arthritis
20180 citationsauthor #12
Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration
201811 citationsauthor #3
Comparison of Serological Biomarkers in Rheumatoid Arthritis and Their Combination to Improve Diagnostic Performance
201843 citationsauthor #7
Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study
201835 citationsauthor #1
The effect of comedication with a csDMARD on drug retention and clinical effectiveness of anti-TNF therapy in patients with axial spondyloarthritis
201810 citationsauthor #10
P024 Comparison of CCP2 and CCP3 assays in a large cohort of established rheumatoid arthritis and controls
20184 citationsauthor #9
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome.
2018329 citationsauthor #14
O025 Unopposed interleukin 18 signalling leads to severe toll like receptor 9-induced macrophage activation syndrome in mice
20180 citationsauthor #7
Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis
201768 citationsauthor #14
International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.
201732 citationsauthor #28
THU0174 Drug retention of tofacitinib versus biologic antirheumatic agents in rheumatoid arthritis: observational data from the swiss scqm registry
20177 citationsauthor #12
OP0093 Il-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro
20170 citationsauthor #8
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition.
2017308 citationsauthor #11
Patients With Xiap Deficiency Have Circulating Free Il-18 Which May Represent A Therapeutic Target
20170 citationsauthor #4
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease
2017271 citationsauthor #1
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis
201724 citationsauthor #19
Rheumatoid arthritis: from basic findings and clinical manifestations to future therapies
20170 citationsauthor #2
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
201710 citationsauthor #4
Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials
201727 citationsauthor #7
[Adverse events of biologic therapies].
20171 citationsauthor #2
The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
201718 citationsauthor #4
IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro
2017115 citationsauthor #8
Deficiency in IL-1 Receptor Type 2 Aggravates K/BxN Serum Transfer-Induced Arthritis in Mice but Has No Impact on Systemic Inflammatory Responses
201720 citationsauthor #7
Rheumatoid arthritis: from basic findings and clinical manifestations to future therapies
20175 citationsauthor #2
Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesis
201722 citationsauthor #4

TIMELINE

1992 8 citations

1993 146 citations

1994 0 citations

1995 67 citations

1996 77 citations

1999 7,016 citations

2000 145 citations

2001 111 citations

2002 870 citations

2003 401 citations

2004 734 citations

2005 592 citations

2006 2,529 citations

2007 1,035 citations

2008 1,379 citations

2009 1,110 citations

2010 8,095 citations

2011 1,292 citations

2012 1,098 citations

2013 1,030 citations

2014 636 citations

2015 1,091 citations

2016 673 citations

2017 1,118 citations

2018 1,126 citations

2019 651 citations

2020 555 citations

2021 196 citations

2022 177 citations

2023 58 citations

Unknown 0 citations

C. Gabay

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT